Walk-in lab testing in West Virginia is giving patients faster, more affordable access to diagnostics—while pushing clinical labs to adapt to a more consumer-driven care model.
Across the clinical laboratory industry, the shift toward consumer-directed healthcare continues to gain momentum. A recent report by the Charleston Gazette-Mail highlights a growing trend in West Virginia of walk-in laboratory services that allow patients to bypass traditional physician referrals for routine diagnostic testing.
For pathologists and clinical lab professionals, this shift represents a significant evolution in the traditional diagnostic workflow. Facilities like Any Lab Test Now and local hospital-affiliated outreach centers are increasingly offering direct-to-consumer (DTC) options, allowing individuals to purchase tests such as lipid panels, glucose levels, DNA, and toxicology screens.
Key Drivers of Walk-In Testing
The article identifies several factors pushing patients toward walk-in labs:
Cost transparency: Many patients with high-deductible health plans are choosing walk-in labs that offer transparent, upfront pricing, often avoiding the “sticker shock” of traditional hospital billing.
Convenience and speed: The ability to walk in without an appointment and receive results via secure online portals—often within 24 to 48 hours—appeals to the modern healthcare consumer.
Proactive health management: There is a growing demographic of proactive patients who wish to monitor chronic conditions or wellness markers more frequently than their annual, insurance-covered physical allows.
“This gives [patients] an opportunity to manage their own health,” said Matt Brooks, director of clinical laboratory services at Marshall Health Network based in Huntington, W.V. “And it gives patients the opportunity to pay for the test without having to go through their insurance.” (Photo credit: Marshall Health Network).
The Changing Role of the Provider
While the convenience is clear, the trend raises questions regarding the interpretation of results. Patients have access to more data, yet they still require professional guidance to put that data into clinical context.
Most walk-in models encourage patients to share their results with their primary care physicians, but the “patient-as-the-customer” model places the initial responsibility for action squarely on the individual.
Implications for Clinical Labs
For traditional clinical laboratories, the growth of walk-in testing in regions like West Virginia serves as a signal to adapt. As patients become more accustomed to retail-style healthcare experiences, laboratories may need to invest more heavily in user-friendly digital interfaces and transparent pricing structures to remain competitive.
This trend also underscores a broader national movement. As more states relax regulations regarding DTC testing, the laboratory’s role is shifting from a behind-the-scenes diagnostic provider to a front-facing participant in the patient’s healthcare.
WHO introduces faster, more accessible TB testing strategies while CDC maintains a targeted, risk-based approach in the United States.
The World Health Organization (WHO) has issued new recommendations aimed at improving access to faster, more efficient tuberculosis (TB) diagnostics by introducing near point-of-care molecular testing, alternative sample collection methods, and pooled testing strategies, according to a news release.
For the first time, WHO is recommending a new class of near point-of-care nucleic acid amplification tests (NPOC-NAATs) that can be deployed in decentralized settings such as primary care clinics and community health centers. These systems are designed to deliver faster results at lower cost compared to traditional laboratory-based molecular platforms, potentially shifting more TB testing closer to the patient.
Clinical laboratory scientists should note that the WHO’s guidelines diverge noticeably from those of the Centers for Disease Control and Prevention (CDC).
The updated guidance also endorses tongue swabs as an alternative specimen type for TB detection, particularly for patients unable to produce sputum. In parallel, WHO recommends sputum pooling as a strategy to improve efficiency and reduce costs, allowing laboratories to increase throughput while conserving reagents in resource-constrained environments.
“These new WHO recommendations mark a major step forward in making TB testing faster and more accessible,” said Tereza Kasaeva, director of WHO’s Department for HIV, TB, Hepatitis & STIs. “WHO urges countries and partners to work together to roll out these guidelines to close persistent diagnostic gaps and ensure that everyone with TB can be diagnosed early and start life-saving treatment without delay.” (Photo credit: WHO)
The recommendations arrive as global diagnostic gaps persist despite international commitments to expand access to rapid molecular testing. Many patients still experience delays due to reliance on sputum samples, centralized laboratory infrastructure, and the high cost of testing platforms.
New WHO Recommendations Emphasize Access and Efficiency
WHO’s updated Module 3: Diagnosis guidelines, expected later this year, reflect a broader shift toward decentralization and scalability in TB diagnostics.
By enabling testing at peripheral healthcare levels, the new NPOC-NAAT systems could reduce turnaround times and expand access in underserved regions. Tongue swabs further simplify sample collection, while pooling strategies offer laboratories a practical way to stretch limited resources without sacrificing diagnostic reach.
Supporting materials, including an operational handbook and implementation toolkit, will guide laboratories and national TB programs through adoption, training, and workflow integration.
CDC Maintains Targeted Testing Approach in the US
In contrast to WHO’s global push for expanded access, the CDC continues to emphasize a targeted testing strategy for tuberculosis in the United States, focusing on high-risk individuals rather than universal screening.
TB case counts and rates have been increasing since 2021, the CDC noted in late 2025. The US saw a 7.9% increase in case count and a 6.9% increase in rate in 2024 as compared to a year earlier. In 2024, there were 10,388 TB cases in the US with a corresponding incidence rate of 3.1 per 100,000 population.
Two Types of TB Infection Tests
The CDC recognizes two primary methods to detect TB infection, though neither distinguishes between latent infection and active disease:
TB blood tests: Preferred for most individuals, particularly those vaccinated with Bacille Calmette-Guérin (BCG). (BCG is primarily used to prevent severe childhood TB particularly in high-prevalence countries. BCG is generally not recommended in the US.)
TB skin test: Still used in certain cases, especially for children under age five, and for baseline testing scenarios requiring a two-step approach.
Five Components of a Full Diagnostic Evaluation
If a patient tests positive or presents symptoms such as chronic cough, night sweats, or weight loss, the CDC recommends a comprehensive evaluation that includes:
Medical history and risk assessment
Physical examination
Chest X-ray
Bacteriologic testing using sputum samples (typically three), including:
NAAT for rapid detection
Sputum smear microscopy
Culture
Drug susceptibility testing to guide treatment decisions
Updated Guidance for Healthcare Personnel
Recent CDC guidance, developed with the National Tuberculosis Controllers Association, reflects a shift in screening practices for healthcare workers:
Baseline TB testing is required upon hire
Routine annual testing is no longer recommended for most healthcare workers
Post-exposure testing is advised immediately and again eight to 10 weeks later if initial results are negative
For 2026, the CDC emphasizes several important nuances for clinicians and laboratories interpreting TB test results. Blood-based interferon-gamma release assays (IGRAs) are strongly preferred for individuals who have received the BCG vaccine, as they are less likely to produce false-positive results compared to skin tests. In addition, for individuals considered low risk for TB, a positive result should be confirmed with a second test—ideally using a different method—before treatment is initiated, helping to avoid unnecessary therapy and ensure diagnostic accuracy.
Implications for Clinical Laboratories
Together, WHO and CDC guidance illustrate a divergence in strategy shaped by global versus domestic needs. WHO’s recommendations prioritize expanded access, decentralization, and cost efficiency—particularly in high-burden or resource-limited settings—while CDC guidance reflects a more targeted, risk-based approach within a lower-incidence environment.
For clinical laboratories, the evolving landscape signals both opportunity and complexity: Adoption of decentralized molecular platforms, validation of alternative specimen types, and optimization of high-throughput workflows such as pooling may become increasingly important as TB diagnostic strategies continue to evolve.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
Doherty Institute researchers unveil an assay that identifies four STIs and antibiotic resistance in under an hour with up to 100% precision.
Researchers at the Peter Doherty Institute for Infection and Immunity in Australia have developed a portable, point-of-care diagnostic tool capable of detecting four major sexually transmitted infections (STIs) simultaneously in under 60 minutes, according to a recent press release.
The device, a next-generation CRISPR-based diagnostic, identifies DNA and RNA for syphilis, herpes simplex virus (HSV), chlamydia, and gonorrhea. Notably, the test also detects a critical antibiotic-resistance marker in gonorrhea, providing a vital tool in the global fight against antimicrobial resistance.
Closing the Diagnostic Gap
The clinical challenge of STIs often lies in their “mimicking” nature, meaning many infections present with nearly identical symptoms, such as genital sores, but require distinct treatment protocols. Without rapid testing, clinicians are often forced to treat based on symptoms alone, leading to potential misdiagnosis.
“Syphilis has long been known as the great mimicker. Correct treatment depends on correct diagnosis,” said Shivani Pasricha, PhD, laboratory head at the Doherty Institute and senior author of a related study published in The Lancet Microbe. “This novel tool enables accurate diagnosis and treatment immediately, without waiting days for laboratory testing or requiring multiple clinic visits.” (Photo credit: Doherty Institute)
Proven Precision
The device has undergone extensive validation, using 900 clinical samples—the largest set ever reported for a CRISPR-based point-of-care device.
“When benchmarked against gold-standard laboratory PCR, the rapid test showed 97–100% accuracy in correctly identifying negative results, a level of precision important for safe, evidence-based treatment decisions,” stated Matthew O’Neill, research support officer at the Doherty Institute and co-first author.
The researchers are now moving toward implementation trials, with a goal of integrating the device into routine clinical use within the next five years.
Overall decline: The combined total of chlamydia, gonorrhea, and syphilis cases fell by 9% compared to 2023, marking the third consecutive year of decline. Despite this, the US still recorded over 2.2 million total infections in 2024.
Syphilis trends:
Primary and secondary syphilis: These highly infectious stages saw a significant 22% decrease from 2023.
Congenital syphilis: In a distressing trend, cases of syphilis passed from mother to child increased for the 12th consecutive year, with nearly 4,000 cases reported in 2024. This represents a nearly 700% increase over the last decade.
Chlamydia and gonorrhea:
Chlamydia cases dropped by 8% from 2023.
Gonorrhea cases declined for the third year in a row, falling by 10%.
Long-term Perspective
While recent years show improvement, the overall STI burden remains 13% higher than it was a decade ago, highlighting the urgent need for the rapid, accessible diagnostic technologies currently being developed by teams like those at the Doherty Institute.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
It is just the latest development in the rapidly evolving area of Alzheimer’s research that the general public is becoming increasingly aware of. Clinical laboratory professionals should continue to monitor this progress.
The study, published in Nature Medicine, demonstrated that the predictive models could estimate the onset of Alzheimer’s symptoms within a margin of roughly three to four years. By estimating when cognitive decline may begin, the approach could help researchers enroll patients in clinical trials at the most informative stages of disease progression, shortening study timelines and improving the evaluation of therapies designed to delay or prevent symptoms.
In September 2025, Dark Daily reported that new clinical guidelines from the Alzheimer’s Association recommend that Alzheimer’s blood tests achieve at least 90% sensitivity and specificity before they can replace established diagnostic tools such as amyloid PET imaging or cerebrospinal fluid testing. The recommendations aim to standardize clinical use of emerging biomarkers—particularly p-tau and amyloid-beta assays—while helping clinicians and laboratories determine when blood-based tests can be used for diagnosis or as triage tools in Alzheimer’s disease evaluation.
Blood Biomarker p-tau217 Provides Early Clock for Alzheimer’s Disease Progression
Alzheimer’s disease currently affects more than seven million Americans, and the economic burden continues to grow. According to the Alzheimer’s Association, health and long-term care costs related to Alzheimer’s and other forms of dementia are projected to reach nearly $400 billion in 2025. Because symptoms often appear years after underlying brain changes begin, researchers have increasingly focused on identifying biomarkers that can detect and track disease earlier.
The new predictive models rely on measuring plasma levels of a protein biomarker known as p-tau217, which reflects the accumulation of amyloid and tau proteins in the brain—two pathological hallmarks of Alzheimer’s disease. These misfolded proteins begin building up many years before symptoms emerge. By analyzing patterns of p-tau217 in blood samples, researchers created what they describe as a biological “clock” that tracks disease progression.
“Our work shows the feasibility of using blood tests, which are substantially cheaper and more accessible than brain imaging scans or spinal fluid tests, for predicting the onset of Alzheimer’s symptoms,” said senior author Suzanne E. Schindler, MD, PhD, an associate professor in the WashU Medicine Department of Neurology. Schindler noted that these models could allow clinical trials of potentially preventive treatments to be performed within a shorter time period.
To develop the models, investigators analyzed data from 603 older adults participating in two major longitudinal research initiatives: the WashU Knight Alzheimer Disease Research Center and the multi-site Alzheimer’s Disease Neuroimaging Initiative. Participants lived independently and were monitored over time for biomarker changes and cognitive decline.
The researchers found that elevated p-tau217 levels in blood correlated strongly with amyloid and tau buildup observed through PET brain imaging. Using this relationship, they estimated how long it typically takes for individuals with elevated biomarker levels to develop cognitive symptoms.
Age Influences Alzheimer’s Symptom Onset as Blood Biomarker Model Gains Validation
Interestingly, the timeline varied by age. Participants who first showed elevated p-tau217 at younger ages experienced longer delays before symptom onset. For example, individuals with elevated levels at age 60 tended to develop symptoms roughly 20 years later, whereas those whose biomarker levels rose at age 80 developed symptoms about 11 years later. The finding suggests that younger brains may be more resilient to the early stages of neurodegeneration.
The predictive approach also proved robust across multiple diagnostic assays measuring p-tau217, including the commercially available PrecivityAD2 blood test. Researchers noted that broader use of blood-based biomarker testing could offer a more accessible and cost-effective alternative to PET imaging or spinal fluid analysis.
For clinical laboratories and diagnostic developers, the findings highlight the growing role of blood-based biomarkers in neurodegenerative disease detection and management. While additional research will be required before such models are used in routine clinical care, investigators say the technology could significantly improve the design of preventive Alzheimer’s trials—and eventually help physicians identify patients most likely to benefit from early interventions.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
Researchers identified distinct blood metabolite signatures that could help clinical laboratories develop noninvasive tests to detect gallbladder cancer earlier and improve diagnostic decision-making.
Metabolomics Identifies Blood Markers for Gallbladder Cancer Detection
Gallbladder cancer remains relatively rare in the United States, affecting about 12,000 people annually and causing roughly 2,000 deaths. However, the disease often carries a poor prognosis because early symptoms are minimal and screening options are limited. In some parts of the world—particularly northern India’s Assam region—the cancer is far more common and frequently diagnosed late. These factors have driven researchers to explore blood-based biomarkers that could support earlier detection and improve patient outcomes.
For laboratory professionals, the study highlights the expanding role of advanced metabolomic analysis in biomarker discovery. Investigators analyzed blood samples from three patient groups: gallbladder cancer patients without gallstones, cancer patients with gallstones, and individuals who had gallstones but no cancer. Using untargeted metabolomics, the team detected hundreds of altered metabolites—180 in gallstone-free cancer cases and 225 in gallstone-associated cases—revealing metabolic patterns that could differentiate malignant disease from benign gallstone conditions. Many of the biomarkers were linked to bile acids and amino acid derivatives associated with tumor development and progression.
A key step in translating these signals into clinically meaningful insight involved computational metabolomics.
Illinois researcher Amit Rai, an assistant professor in the Department of Crop Sciences, part of the College of Agricultural, Consumer and Environmental Sciences, emphasized the importance of careful data interpretation in large-scale biochemical studies. “Once the raw data are generated, the real challenge is making biological sense of it. Properly annotating metabolites and analyzing their patterns is what allows us to move from signals in the data to meaningful insight about disease mechanisms.”
Blood-Based Biomarkers Could Enable Earlier, Noninvasive Detection of Gallbladder Cancer
The researchers ultimately identified metabolic signatures capable of distinguishing gallbladder cancer patients with and without gallstones. According to study leader Pankaj Barah, assistant professor, Tezpur University, “Our findings show that changes in certain blood metabolites can clearly distinguish gallbladder cancer cases with and without gallstones. This raises the possibility of developing simple blood-based tests that could support earlier diagnosis.”
For clinical laboratories, such testing could eventually offer a practical, noninvasive approach to identifying gallbladder cancer before symptoms become severe. Study co-author Subhash Khanna, gastrointestinal surgeon at Swagat Super Specialty and Surgical Hospital in India, noted that “identifying blood-based metabolic markers provides a practical pathway toward earlier diagnosis and more informed clinical decision-making.”
While additional multicenter studies will be necessary before the biomarkers can be translated into routine clinical use, the research provides an important proof of concept. It also highlights how laboratory-driven disciplines—such as metabolomics, advanced analytics, and interdisciplinary collaboration—are increasingly shaping the future of cancer diagnostics.
High negative predictive value and real-time insights make donor-derived cell-free DNA testing a strategic addition to molecular diagnostic menus.
A new blood test that measures donor-derived cell-free DNA (dd-cfDNA) is reshaping post-transplant surveillance by offering clinical laboratories a powerful, noninvasive tool to detect organ injury earlier than traditional methods.
The assay enables physicians to monitor graft health through a blood draw—potentially reducing reliance on invasive tissue biopsies and allowing for more timely intervention. The research was outlined in a recent article published by the College of American Pathologists, “Utilizing Cell-Free DNA Technologies for Clinically Significant Biomarkers in Solid Organ Transplantation,” about the clinical application of cell-free DNA technologies in solid organ transplantation.
“This new test functions as an early warning system, providing real-time insight into transplant health using a simple blood draw,” shares co-author Julianne Szczepanski, MD, FCAP, clinical instructor, Pathology, University of Michigan Health. (Photo credit: University of Michigan Health)
For lab professionals, dd-cfDNA represents a meaningful advance in transplant diagnostics. When cells from a transplanted organ are injured—whether due to rejection, infection, or ischemia—they release fragments of donor DNA into the recipient’s bloodstream. Quantifying these fragments provides a dynamic biomarker of graft injury. In stable patients, donor-derived DNA levels remain low. Rising levels, however, may indicate early organ damage, often before clinical symptoms or traditional markers become apparent. This creates an opportunity for laboratories to deliver actionable, real-time data that directly informs patient management decisions.
The clinical utility of dd-cfDNA testing is now supported by professional guidelines for kidney and heart transplant recipients. Studies demonstrate that the assay has a strong negative predictive value, meaning low dd-cfDNA levels can reliably rule out rejection. For laboratory directors and pathologists, this is significant because the findings show that high-confidence, rule-out testing can help reduce unnecessary biopsies, lower procedural risk, and decrease healthcare costs. At the same time, elevated results can identify patients who require closer surveillance, immunosuppression adjustments, or further diagnostic workup.
Broader Use Increases Demand for Lab Expertise
Importantly, while dd-cfDNA testing is highly sensitive to graft injury, it does not always specify the underlying cause. Elevated levels may reflect rejection, infection, or other forms of tissue damage, requiring correlation with clinical findings and additional testing. This reinforces the laboratory’s role not just in generating results, but in guiding interpretation and supporting multidisciplinary transplant teams.
Ongoing research aims to expand dd-cfDNA applications beyond kidney and heart transplantation to include liver and lung recipients. Investigators are also exploring refinements that could differentiate types of organ injury, further enhancing diagnostic specificity.
For clinical laboratories, dd-cfDNA testing underscores the expanding role of molecular diagnostics in precision transplant medicine—offering a scalable, patient-centered approach to graft monitoring that aligns with broader trends toward minimally invasive, data-driven care.
